肠道微生物群的调控机制 - - 短链脂肪酸信号轴缓慢过渡性便秘和多目标干预的进展
Shi Hong Liu1,2, Xue Fang Yang1, Lei Liang3
1Department of Integrated Traditional Chinese and Western Medicine of Colorectal and Anal Diseases, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Frontiers in microbiology
|December 10, 2025
概括
慢过渡性便秘 (STC) 与影响结肠机动性的肠道微生物群失衡有关. 了解肠道微生物群-短链脂肪酸 (SCFA) 轴为个性化的STC疗法提供了新的途径.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 缓慢过渡性便秘 (STC) 是一种普遍存在的疾病,对健康和经济产生重大影响.
- 肠道微生物群-短链脂肪酸 (SCFA) 轴与STC的病理生理学有关.
- 通过神经,上皮和免疫路径,SCFA会影响结肠运动.
研究的目的:
- 审查SCFA在调节结肠运动中的作用.
- 评估STC的多目标干预措施.
- 为STC管理提出一个精准医学框架.
主要方法:
- 关于SCFA-运动轴的当前知识的文献综合.
- 对STC干预的随机对照试验和元分析的评估.
- 整合多omics数据进行个性化治疗.
主要成果:
- 酸,特别是酸,酸和酸,通过各种机制影响运动性.
- SCFA受体FFAR2和FFAR3表现出偏向的信号传递和异体化.
- 多目标干预措施显示了可变的疗效和安全性.
结论:
- 对于STC,建议采用精准医学方法,整合微生物组,代谢组和遗传数据.
- 需要进一步研究长期安全性,大型多中心试验和用于响应者预测的机器学习.
- 该审查提供了基于机制的个性化STC护理的路线图.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
676
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
676
Drugs Affecting GI Tract Motility: Other Laxatives
983
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
983
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
508
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
508
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
855
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
855
Irritable Bowel Syndrome I: Introduction
890
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
890
Drugs for Treatment of Diarrhea-Predominant IBS
598
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
598


